You are here
November 19, 2024
Mapping how cancers form and spread
At a Glance
- 3D maps of cancer produced by an 麻豆传媒 initiative provide critical information on how tumors develop, spread, and respond to treatments.
- These maps provide a better understanding of the development and progression of cancer, which could eventually lead to new prevention and treatment strategies.
A tumor can contain millions of cancerous cells, many of which may behave and respond to treatments differently. In addition, tumors harbor other types of cells, such as immune cells, which migrate from elsewhere in the body. Tumors can also interact in complex ways with surrounding tissues, known as the tumor microenvironment.
All these factors can influence if, how, and where a tumor grows and spreads. Recent large research projects such as The Cancer Genome Atlas have uncovered many specific genetic changes in cancer cells that can help drive tumor growth. But how these changes emerge and change over time and location in a tumor have remained largely a mystery. Such information is needed to better understand why some treatments don鈥檛 work in some tumor types and how resistance to treatment develops over time.
In 2018, NIH launched the Human Tumor Atlas Network (HTAN) as part of the Cancer Moonshot鈩 initiative. The Network funded research teams across the country to develop new imaging, genetic analysis, and computational tools to map out the workings of single cells within a tumor.
Overall, the network gathered tissue samples from 21 different organ types聽taken from almost 2,000 people. These included samples from tumors and pre-cancerous growths, and cells from blood cancers like leukemia. The latest results from HTAN appeared on October 30, 2024, in a suite of papers in Nature journals.
In one of the new studies, a team led by Dr. Li Ding from Washington University in St. Louis closely analyzed breast, colorectal, pancreatic, kidney, and uterine cancer samples. They were able to identify distinct substructures, which they called microregions, within many tumors.
They found that cells in different microregions within the tumors often behaved differently. For example, cells closer to the core of tumors used more energy. Cells at the edges of tumors had more interactions with the immune system. In some tumors, different genetic mutations in different microregions could drive tumor growth. Such diversity can pose a challenge for treatment using therapies to target specific mutations.
Such differences in tumor cell behavior couldn鈥檛 be mapped to the 3D structure of tumors before the spatial mapping techniques developed by HTAN.
鈥淲e understood that cancer cells, immune cells, and structural cells were all present in [a] tumor, sometimes protecting the cancer from chemotherapy and immune system attack, but now we can actually see those battle lines,鈥 Ding says. 鈥淲e now have the ability to see how regions of the tumor differ in 3D space and how the behavior changes in response to therapy or when the tumor spreads to other organs.鈥
Other papers in the collection provided details about how various cancers develop and spread over time. For example, a team from Stanford University showed that colorectal tumors can contain populations derived from multiple cells that turned cancerous independently, instead of from a single ancestor cell. Other teams tracked how some cancer types first arise, and then later gain the ability to metastasize elsewhere in the body.
A second phase of HTAN now aims to further build on these results. 鈥淭his work聽is helping us see and understand tumors in ways we never could before,鈥 says聽Dr. W. Kimryn Rathmell, director of NIH鈥檚 National Cancer Institute. 鈥淭hese resources will spur insights and innovations for years to come.鈥
Related Links
- Cell Atlases Give Detailed Views of Human Organs
- Y Chromosome Affects Cancer Growth
- Most Tumors in Body Share Important Mutations
- Genomic Analysis of 33 Cancer Types Completed
- Study Reveals Large Number of Cancer Genes
References: Mo CK, Liu J, Chen S, Storrs E, Targino da Costa ALN, Houston A, Wendl MC, Jayasinghe RG, Iglesia MD, Ma C, Herndon JM, Southard-Smith AN, Liu X, Mudd J, Karpova A, Shinkle A, Goedegebuure SP, Abdelzaher ATMA, Bo P, Fulghum L, Livingston S, Balaban M, Hill A, Ippolito JE, Thorsson V, Held JM, Hagemann IS, Kim EH, Bayguinov PO, Kim AH, Mullen MM, Shoghi KI, Ju T, Reimers MA, Weimholt C, Kang LI, Puram SV, Veis DJ, Pachynski R, Fuh KC, Chheda MG, Gillanders WE, Fields RC, Raphael BJ, Chen F,聽Ding L. Nature. 2024 Oct;634(8036):1178-1186. doi: 10.1038/s41586-024-08087-4. Epub 2024 Oct 30. PMID:聽39478210.
. Nature. 2024 Oct 30.
Funding: NIH鈥檚 National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute of Neurological Disorders and Stroke (NINDS), National Human Genome Research Institute (NHGRI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of General Medical Sciences (NIGMS), and National Institute of Biomedical Imaging and Bioengineering (NIBIB); Damon Runyon Cancer Research Foundation; Stanley Cohen Innovation Fund; Howard Hughes Medical Institute; National Science Foundation; Burroughs Wellcome Fund; American Association for Cancer Research, Stand Up to Cancer; Pershing Square Sohn Cancer Research Alliance; Starr Cancer Consortium; Josie Robertson Investigators Program; Barbara and Stephen Friedman Predoctoral Fellowship; Gerry Metastasis and Tumour Ecosystems Center.